Although the clinical efficacy and safety profiles of the anti-PD-1/PD-L1 therapeutics currently used to treat lung cancer are promising, a large proportion of patients are unresponsive or eventually progress, which highlights the need for further research into novel agents targeting the PD-1/PD-L1 axis [10]. The gene discussed is CD274; the disease is lung cancer.